トップページ  > 研究業績(秋葉)

Publication:Hisaya Akiba

2021

1) Takeshige, T., Harada, N., Harada, S., Ishimori, A., Katsura, Y., Sasano, H., Sandhu, Y., Matsuno, K., Makino, F., Ito, J., et al. (2021) Chitin induces steroid-resistant airway inflammation and airway hyperresponsiveness in mice. Allergol Int Feb 24:S1323-8930(21)00008-3.

2) Omori, S., Tsugita, M., Hoshikawa, Y., Morita, M., Ito, F., Yamaguchi, S.I., Xie, Q., Noyori, O., Yamaguchi, T., Takada, A., et al. (2021). Tim4 recognizes carbon nanotubes and mediates phagocytosis leading to granuloma formation. Cell Rep 34, 108734.

2020

1) Wei, W., Jiang, D., Lee, H.J., Engle, J.W., Akiba, H., Liu, J., and Cai, W. (2020) ImmunoPET Imaging of TIM-3 in Murine Melanoma Models. Adv Ther Jul;3(7):2000018.

2) Narimatsu, A., Hattori, T., Usui, Y., Ueno, H., Funaki, T., Komatsu, H., Nakagawa, H., Akiba, H., and Goto, H. (2020). Blockade of costimulatory CD27/CD70 pathway promotes corneal allograft survival. Exp Eye Res 199, 108190.

2018

1) Matsuno, K., Harada, N., Harada, S., Takeshige, T., Ishimori, A., Itoigawa, Y., Katsura, Y., Kodama, Y., Makino, F., Ito, J., et al. (2018). Combination of TWEAK and TGF-beta1 induces the production of TSLP, RANTES, and TARC in BEAS-2B human bronchial epithelial cells during epithelial-mesenchymal transition. Exp Lung Res 44, 332-343.

2) Yasuda, M., Harada, N., Harada, S., Ishimori, A., Katsura, Y., Itoigawa, Y., Matsuno, K., Makino, F., Ito, J., Ono, J., et al. (2018). Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E. Allergy Asthma Clin Immunol 14, 72.

2017

1) Isshiki T., Akiba H., Nakayama M., Harada N., Okumura K., Homma S., Miyake S. (2017) Anti-TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice. J Immunol 199, 3733-3737.

2016

1) Kunishige T., Taniguchi H., Terada M., Akiba H., Yagita H., Abe R., Hori J. (2016) Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.Invest Ophthalmol Vis Sci 57, 6815-6823.

2) Elhai, M., Avouac, J., Hoffmann-Vold, A. M., Ruzehaji, N., Amiar, O., Ruiz, B., Brahiti, H., Ponsoye, M., Frechet, M., Burgevin, A., Pezet, S., Sadoine, J., Guilbert, T., Nicco, C., Akiba, H., Heissmeyer, V., Subramaniam, A., Resnick, R., Molberg, O., Kahan, A., Chiocchia, G., and Allanore, Y. (2016) OX40L blockade protects against inflammation-driven fibrosis. .Proc Natl Acad Sci USA 113, E3901-E3910.

2015

1) Tripathi, S., Chabtini, L., Dakle, P. J., Smith, B., Akiba, H., Yagita, H., and Guleria, I. (2015) Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PloS one 10, e0123439.

2) Katsura, Y., Harada, N., Harada, S., Ishimori, A., Makino, F., Ito, J., Kamachi, F., Okumura, K., Akiba, H., Atsuta, R., and Takahashi, K. (2015) Characteristics of alveolar macrophages from murine models of OVA-induced allergic airway inflammation and LPS-induced acute airway inflammation. Exp Lung Res 41, 370-382.

3) Kamachi, F., Isshiki, T., Harada, N., Akiba, H., and Miyake, S. (2015) ICOS promotes group 2 innate lymphoid cell activation in lungs. Biochem Biophys Res Commun 463, 739-745.

2014

1) Nozaki, Y., Kitching, A. R., Akiba, H., Yagita, H., Kinoshita, K., Funauchi, M., and Matsumura, I. (2014) Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Fas(lpr) mice. Am J Physiol Renal Physiol 306, F1210-1221.

2) Kaneyama, T., Tomiki, H., Tsugane, S., Inaba, Y., Ichikawa, M., Akiba, H., Yagita, H., Kim, B. S., and Koh, C. S. (2014) The TIM-3 pathway ameliorates Theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 26, 369-381.

3) Kamachi, F., Harada, N., Usui, Y., Sakanishi, T., Ishii, N., Okumura, K., Miyake, S., and Akiba, H. (2014) OX40 ligand regulates splenic CD8- dendritic cell-induced Th2 responses in vivo. Biochem Biophys Res Commun 444, 235-240.

2013

1) TIM-4 has dual function in the induction and effector phases of murine arthritis.
Abe Y, Kamachi F, Kawamoto T, Makino F, Ito J, Kojima Y, Moustapha Ael D, Usui Y, Yagita H, Takasaki Y, Okumura K, Akiba H. J Immunol. 2013;191(9):4562-72.

2) Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival. Yeung MY, McGrath MM, Nakayama M, Shimizu T, Boenisch O, Magee CN, Abdoli R, Akiba H, Ueno T, Turka LA, Najafian N. J Immunol. 2013;191(8):4447-55.

3) TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Takeya M, Viollet B, Yagita H, Jinushi M. Immunity. 2013;39(6):1070-81.

4) Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Ohyagi H, Onai N, Sato T, Yotsumoto S, Liu J, Akiba H, Yagita H, Atarashi K, Honda K, Roers A, Muller W, Kurabayashi K, Hosoi-Amaike M, Takahashi N, Hirokawa M, Matsushima K, Sawada K, Ohteki T. Immunity. 2013 ;39(3):584-98.

5) T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, van Puijvelde GH.
Arterioscler Thromb Vasc Biol. 2013;33(11):2558-65.

6) Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. Shimmura-Tomita M, Wang M, Taniguchi H, Akiba H, Yagita H, Hori J. PLoS One. 2013;8(5):e63620.

7) TIM-3 regulates innate immune cells to induce fetomaternal tolerance. Chabtini L, Mfarrej B, Mounayar M, Zhu B, Batal I, Dakle PJ, Smith BD, Boenisch O, Najafian N, Akiba H, Yagita H, Guleria I. J Immunol. 2013;190(1):88-96.

8) Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Cancer Immunol Immunother. 2013;62(4):629-37.

2012

1) Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice. Makino F, Ito J, Abe Y, Harada N, Kamachi F, Yagita H, Takahashi K, Okumura K, Akiba H. Am J Respir Cell Mol Biol. 2012;47(3):298- 305.


2) Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development. Sugiyama M, Nakato G, Jinnohara T, Akiba H, Okumura K, Ohno H, Yoshida H. Int Immunol. 2012;24(6):369-78.


3) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. Nat Immunol. 2012;13(9):832-42.


4) Antibodies against B7-DC with differential binding properties exert opposite effects. Ritprajak P, Hashiguchi M, Akiba H, Yagita H, Okumura K, Azuma M. Hybridoma. 2012;31(1):40-7.


5) Endogenous Tim-1 (Kim-1) promotes T-cell responses and cell-mediated injury in experimental crescentic glomerulonephritis. Nozaki Y, Nikolic-Paterson DJ, Snelgrove SL, Akiba H, Yagita H, Holdsworth SR, Kitching AR. Kidney Int. 2012 ;81(9):844-55.


6) Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J, Akiba H, Yagita H, Makino H. Endocrinology. 2012;153(2):612-20.


2011

1) Anti-T cell immunoglobulin and mucin domain-2 monoclonal antibody exacerbates collagen-induced arthritis by stimulating B cells. Kawamoto T, Abe Y, Ito J, Makino F, Kojima Y, Usui Y, Ma J, Morimoto S, Yagita H, Okumura K, Takasaki Y, Akiba H. Arthritis Res Ther. 2011;13(2):R47.


2) TIM-1 signaling in B cells regulates antibody production. Ma J, Usui Y, Takeda K, Harada N, Yagita H, Okumura K, Akiba H. Biochem Biophys Res Commun. 2011; 406(2):223-8.


3) Tim-1 promotes cisplatin nephrotoxicity. Nozaki Y, Nikolic-Paterson DJ, Yagita H, Akiba H, Holdsworth SR, Kitching AR. Am J Physiol Renal Physiol. 2011;301(5): F1098-104.


4) Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM. J Clin Invest. 2011;121(9):3645-56.


5) Wound-induced TGF-β1 and TGF-β2 enhance airway epithelial repair via HB-EGF and TGF-α. Ito J, Harada N, Nagashima O, Makino F, Usui Y, Yagita H, Okumura K, Dorscheid DR, Atsuta R, Akiba H, Takahashi K. Biochem Biophys Res Commun. 2011;412(1):109-14.


6) Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Cancer Res. 2011;71(10):3540-51.


7) The TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury. Rong S, Park JK, Kirsch T, Yagita H, Akiba H, Boenisch O, Haller H, Najafian N, Habicht A. J Am Soc Nephrol. 2011;22(3):484-95.

2010

1) TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. Yamanishi Y, Kitaura J, Izawa K, Kaitani A, Komeno Y, Nakamura M, Yamazaki S, Enomoto Y, Oki T, Akiba H, Abe T, Komori T, Morikawa Y, Kiyonari H, Takai T, Okumura K, Kitamura T. J Exp Med. 2010 ;207(7):1501-11.


2) Expression and function of inducible costimulator on peripheral blood CD4+ T cells in Behcet's patients with uveitis: a new activity marker? Usui Y, Takeuchi M, Yamakawa N, Takeuchi A, Kezuka T, Ma J, Matsuda R, Okunuki Y, Akiba H, Goto H. Invest Ophthalmol Vis Sci. 2010;51(10):5099-104.


3) TIM-3: a novel regulatory molecule of alloimmune activation. Boenisch O, D'Addio F, Watanabe T, Elyaman W, Magee CN, Yeung MY, Padera RF, Rodig SJ, Murayama T, Tanaka K, Yuan X, Ueno T, Jurisch A, Mfarrej B, Akiba H, Yagita H, Najafian N. J Immunol. 2010;185(10):5806-19.


4) T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW, Najafian N, Kupiec-Weglinski JW. Gastroenterology. 2010;139(6):2195-206.


5) Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, Kato M, Miyazawa M. J Immunol. 2010;184(9):4696-707.


6) Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD. Fujimura J, Takeda K, Kaduka Y, Saito M, Akiba H, Yagita H, Yamashiro Y, Shimizu T, Okumura K. Pediatr Transplant. 2010;14(4):540-8.


7) The emerging role of T cell immunoglobulin mucin-1 in the mechanism of liver ischemia and reperfusion injury in the mouse. Uchida Y, Ke B, Freitas MC, Ji H, Zhao D, Benjamin ER, Najafian N, Yagita H, Akiba H, Busuttil RW, Kupiec-Weglinski JW. Hepatology. 2010;51(4):1363-72.


2009

1) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H, Okumura K. Blood. 2009;113(16):3821-30.

2) RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. Knoop KA, Kumar N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, Akiba H, Yagita H, Kiyono H, Williams IR. J Immunol. 2009 ;183(9):5738-47.

3) Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Yuan X, Ansari MJ, D'Addio F, Paez-Cortez J, Schmitt I, Donnarumma M, Boenisch O, Zhao X, Popoola J, Clarkson MR, Yagita H, Akiba H, Freeman GJ, Iacomini J, Turka LA, Glimcher LH, Sayegh MH. Proc Natl Acad Sci U S A. 2009;106(26):10734-9.

4) Roles of PU.1 in monocyte- and mast cell-specific gene regulation: PU.1 transactivates CIITA pIV in cooperation with IFN-gamma. Ito T, Nishiyama C, Nakano N, Nishiyama M, Usui Y, Takeda K, Kanada S, Fukuyama K, Akiba H, Tokura T, Hara M, Tsuboi R, Ogawa H, Okumura K. Int Immunol. 2009;21(7):803-16.

5) RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. Totsuka T, Kanai T, Nemoto Y, Tomita T, Okamoto R, Tsuchiya K, Nakamura T, Sakamoto N, Akiba H, Okumura K, Yagita H, Watanabe M. J Immunol. 2009;182(10):6079-87.

6) Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice. Usui Y, Takeuchi M, Hattori T, Okunuki Y, Nagasawa K, Kezuka T, Okumura K, Yagita H, Akiba H, Goto H. Arch Ophthalmol. 2009;127(4):514-9.

7) Notch signaling confers antigen-presenting cell functions on mast cells. Nakano N, Nishiyama C, Yagita H, Koyanagi A, Akiba H, Chiba S, Ogawa H, Okumura K. J Allergy Clin Immunol. 2009;123(1):74-81.e1.

2008

1) B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. Nagashima O, Harada N, Usui Y, Yamazaki T, Yagita H, Okumura K, Takahashi K, Akiba H. J Immunol. 2008;181(6):4062-71.

2) A novel ICOS-independent, but CD28- and SAP-dependent, pathway of T cell-dependent, polysaccharide-specific humoral immunity in response to intact Streptococcus pneumoniae versus pneumococcal conjugate vaccine. Chen Q, Cannons JL, Paton JC, Akiba H, Schwartzberg PL, Snapper CM. J Immunol. 2008 ;181(12):8258-66.

3) The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, Popoola J, Wang Y, Yagita H, Akiba H, Ansari MJ, Yang J, Turka LA, Rothstein DM, Padera RF, Najafian N, Sayegh MH. J Clin Invest. 2008 ;118(2):742-51.

4) Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis. Wong MG, Suzuki Y, Tanifuji C, Akiba H, Okumura K, Sugaya T, Yamamoto T, Horikoshi S, Tan SY, Pollock C, Tomino Y. J Am Soc Nephrol. 2008;19(2):290-7.

5) Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, Okumura K, Akiba H, Yagita H, Ueno H. Int Arch Allergy Immunol. 2008;146(1):36-43.

2007以前

別紙参照

Copyright c 2013 JUNTENDO All Rights Reserved.